Ketamine-derived nasal spray provides new option for resistant depression

Spravato (esketamine) works in a different way to existing antidepressants, and has been shown to lessen symptoms as early as 24 hours after dosing.

by Chloe Harman
Patients who have not responded to at least 2 different antidepressants in the current depressive episode are considered to have treatment-resistant depression. | GETTY IMAGES
Patients who have not responded to at least 2 different antidepressants in the current depressive episode are considered to have treatment-resistant depression. | GETTY IMAGES

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package